Tracon Pharmaceuticals, Inc.
San Diego, CA · CIK 0001394319 · Biotech · Defunct
therapeutic candidates targeting oncology and vascular diseases (formerly in clinical development)
traconpharma.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $57M
- 4 Form D · Apr 2018
- 102 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 25
- 7 granted · 18 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20092011201320152017
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $750,000 | |
| Private capital raised | Form D · SEC | $16,500,002 | |
| Private capital raised | Form D · SEC | $1,000,000 | |
| Private capital raised | Form D · SEC | $38,673,734 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2435 | SPIRIFY PHARMA INC | — | — |
| 2436 | ENDURX PHARMACEUTICALS, INC. | — | — |
| 2437 | Palvella Therapeutics, Inc. | — | $63M |
| 2438 | Tracon Pharmaceuticals, Inc. | — | $57M |
| 2439 | VELOCITY LABORATORIES, LLC | — | — |
| 2440 | BRANCHPOINT BIOSCIENCES INC. | — | — |
| 2441 | SKROOT LABORATORY INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Bonne AdamsExecutive Officer
- PATRICIA BITARExecutive Officer
- John BoltonDirector
- James CantrellDirector
- William ComerDirector
- Kenji HaradaDirector
- Timothy HoferExecutive Officer
- Hironori HozojiDirector
- Myoung-Ok KwonDirector
- WILLIAM LARUEDirector
- Bryan LeighExecutive Officer
- Bertrand LiangDirector
- J. LobellDirector
- H LOGANExecutive Officer
- MARTIN MATTINGLYDirector
- Sharon RealExecutive Officer
- Charles TheuerDirector · Executive Officer
- CHARLES THEUERDirector · Executive Officer
- J. TwifordDirector
- J. TWIFORDDirector
- PAUL WALKERDirector
- TED WANGDirector
- STEPHEN WORLANDDirector
Patents
- Endoglin Antibodiesapplication
- Use Of Anti-endoglin Antibodies For Treating Ocular Fibrosisgranted
- Antibody Formulations and Uses Thereofgranted
- Anti-endoglin Antibodies And Uses Thereofapplication
- Anti-Endoglin Antibodies and Uses Thereofgranted
- Antibody Formulations and Uses Thereofapplication
- Endoglin Antibodiesapplication
- Endoglin Antibodiesgranted
- Anti-endoglin Antibodies And Uses Thereofgranted
- Potentiation Of Anti-cancer Activity Through Combination Therapy With Ber Pathway Inhibitorsapplication
- Endoglin Antibodiesgranted
- Endoglin Antibodiesgranted
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.